{"name":"selectION Therapeutics GmbH","slug":"selection-therapeutics-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPYXFuQjBrYWtyTmZENkF5ZGVKQm9HNWRjSDZsX3dqYXdwdkZueGMzdGxTUl9fZXh1YjktMTB5bjVTY3VJSU03V3pUdGtFTTFCWlhST0l4cEpQOVFpUTU2b0xhcEdOd3drMUlOdFRGNmN3dWRKVkloVGRoZzVhVjJwOWNpeDIzcWpXSzRLRjBaQ0dIS3k3bmxaNVR3?oc=5","date":"2026-03-10","type":"pipeline","source":"Investing News Network","summary":"SVN-114 selected as the lead candidate for PTSD discovery programme - Investing News Network","headline":"SVN-114 selected as the lead candidate for PTSD discovery programme","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPV21mQjdRNmMxTmVyTDEwTzNQMzVQREdyNnpGYzQyWWNqTERrLThYMFFwU2FEVnRNWnlMWF9zblJrYmpVSFIyZTJYX3BuOW81ZmtiTVBFajlIOFptc3dCVUt6bEk2d3BJaURIaGE5cDlxY0hlck9vYnhvYzhPdFJPYlQ5NTQtU1JRbV9RMEhPdXFqRkRIaFpNa0RWTVlkRHRQVFlNelIyQktJQQ?oc=5","date":"2026-02-12","type":"pipeline","source":"T. Rowe Price","summary":"Health care’s next chapter: Opportunities in an era of transformation - T. Rowe Price","headline":"Health care’s next chapter: Opportunities in an era of transformation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxOWGdEbVEyOWNzRERvT0I5dHhRZ0FzR1YxRm45X09xSjFTbkxreC1NUEZmZHVWYWR3anB0N3VOMEpEWGpBSFhSRnpHMHlDRVBGRE12Z3lpN2k0Sm9DRlhvMF8tbXc3ZHZ5QVRqM1V0cTlwaldZTXBYb01qcm5ZcnFTckIteWhpSV9IcVVEdWx4RXJsQnpuWnU2M1BHSVFkR2FSNnFTZ284eGxnc2tVS2FUTGQ1XzViS29WRmNaenNjOFFkMnVQTHlJd1pEcFBVNVdTbUlsWV9BSHB3bHFWZ2RudnBNVm1VUDBZOVUxUW5nUHQ?oc=5","date":"2026-02-12","type":"trial","source":"GlobeNewswire","summary":"Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices - GlobeNewswire","headline":"Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQSHlMUFFCSGNuM3o2RUlDaXhHTG5OUlZ1dGlqT3RMQndrUUV1M2xtWER5dGNfelVMZWRHbGJjaGNyOE9uUmlOZlpWcnRvU3k4VXNMODlRTkhxWmY0T2c5R19MRC1sT3hERjBxdWhKQ1d4LUhZOHg4aXBtc054MEtNRTFRa1JkdnF1WDFlcnh5SmU5YlprUGxvdjcyREN6Ni1EVlV6ZXBVWHJUeV91ekl0VUNPQQ?oc=5","date":"2026-01-15","type":"pipeline","source":"BioSpace","summary":"Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement - BioSpace","headline":"Fresenius Kabi, TQ Therapeutics Announce Cell Therapy Technology Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOeUsweWx5T2tXTTZwVkk4ZVhpNldFSEEycnJxWHVoUmxQQklDclluODBCWFJhaFE3Q0N4XzY3TzQ4eUFKQ2hVZ1VWQnFybE5FSm42S1BRQlZLU3hpa21GbW1UUF80eFNqalU4UE94bG5mZjQ2UWUwOG5zVmpKSEVfaXVsbENGVjcxUmxyREh6eWZ6SVdHMWRoSE9ENGp4dw?oc=5","date":"2025-12-11","type":"pipeline","source":"European Biotechnology Magazine","summary":"Disco Pharmaceuticals GmbH expands seed financing - European Biotechnology Magazine","headline":"Disco Pharmaceuticals GmbH expands seed financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxOSDNNUkZxOGtkYlNIeVlSNHM1cGNoa19XdjBzS0FvV2xGb0YtbENRZzQ5c1NqaWRuaFFXSlkzWndHUXlfMmhKTzNpU3RjQnhPVmt6Z1MyZjhKX0ZYM0h4NE5aS3NvdDJpYUNDM0pSWWhmbVpnaHIyTHZDS0lVRFJveXdnMXB3N2hQblJvUlpMRE5DMVRTT21peHE1UVJoVmhqWk1r?oc=5","date":"2025-12-10","type":"pipeline","source":"European Biotechnology Magazine","summary":"Selecting a CDMO for Custom Activated PEGs - European Biotechnology Magazine","headline":"Selecting a CDMO for Custom Activated PEGs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE91YlFIa2Q4OHdXTjhnV2VtdTdTZFg1YUdvTnZLSGZobGFRbWJFMDNMZFZRWlYwajczbi1VRzdHR190N2ZrQnRHU0pBbnRodi11TV9WRHhqTGNLZjUwbjBN?oc=5","date":"2025-07-01","type":"pipeline","source":"Nature","summary":"Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors - Nature","headline":"Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOLXFwN2YxMThOZEQ4Zm5EWnM5X3hZWlozQkJ6a3BFM0tiTGd6TXgwSDRNajE3SVBoNVU3MlJ4eDR4OXhJa2F6bGt2NmZwd2Jjc3A1UExZRm5SeHZvSGVOMlk3SjZ6aWpsb2pYQ1FvNzRnVXpxb3RPcVZpaUg4Q1RUd2RKSkZJdU9l?oc=5","date":"2025-06-03","type":"pipeline","source":"Contract Pharma","summary":"Early Choices, Lasting Impact in Cell & Gene Therapy - Contract Pharma","headline":"Early Choices, Lasting Impact in Cell & Gene Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNTTlkdGlsNmlQWF80V1U4RE9kXzhnTHBuLUU3MGlvVHA4MlYyR1U4WGs4TENPTWxsbWxMWXpIdVM1bEFxZkhNVHd2SHBDa1BWS3NRcjl4dGpsWU5xQktXSE4xNHVjNWVFSXpub0d0T25CcEM5SUFpSmFVcHA1U3RDTg?oc=5","date":"2025-05-28","type":"deal","source":"Manufacturing Chemist","summary":"TQ Therapeutics acquires cell therapy specialist, Juno Therapeutics - Manufacturing Chemist","headline":"TQ Therapeutics acquires cell therapy specialist, Juno Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQdUNlMUNGVTM2bnBSSHhMQ3gza29wbll4OFV6U1k1Z1A3UDd2YmxENmZKeFJVc2o2cGhHa3d0aXhGa0tnTUJyOTFvT1E1Qzc5aTNYdXFtR2dLTS04MXpWNnoyeTBfa3Z0UDFEVkdta2JlUm13NGVqd3dsRGpLWjNTN3VDQ0FGSnM3N0RZR3UtdF9fWW9yZVhZaldvSzgwV2FqNndkbVZWZmlXdHRlaTFVYXBPTjhuMWkzYmNiWjRJOVBfVVV0U01EVVF6Zw?oc=5","date":"2025-05-09","type":"pipeline","source":"Dove Medical Press","summary":"PPA - Dove Medical Press","headline":"PPA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNQk1XMjRxY3VBcjY4RzZRM1JUTzBvZ01uNXF3Z1VhX0lSMEJ0cDZYNWtvWEJCOV9YcXJJOHMzWTk1U0ttRkc3amFITjZieU4yYzFiZ3J4N0NXR1Q2dW9zODRHUU1kT3piUS1BeHBSdGpBWFZtSzdyTmkyUEF4cU50b1pacjZOYnc2Y1E?oc=5","date":"2024-02-13","type":"pipeline","source":"pharmacytimes.com","summary":"Advancing Treatment Selection in CLL Management - pharmacytimes.com","headline":"Advancing Treatment Selection in CLL Management","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE80Rk93UlV4R3VwU215MXhYTmtMaXFCQUN2cXBZM0VGXzd4OEZGWmF2SFo5aVBvOWJPR3RuU1JIdkJaWVhOMkhpWndFZENuWGtVMllfbEppYw?oc=5","date":"2022-06-01","type":"trial","source":"jnm.snmjournals.org","summary":"Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial - jnm.snmjournals.org","headline":"Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}